Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Amortization of Deferred Charges: 2020-2021

Historic Amortization of Deferred Charges for Foghorn Therapeutics (FHTX) over the last 2 years, with Dec 2021 value amounting to $58,000.

  • Foghorn Therapeutics' Amortization of Deferred Charges fell 1.69% to $58,000 in Q4 2021 from the same period last year, while for Dec 2021 it was $318,000, marking a year-over-year increase of 33.61%. This contributed to the annual value of $318,000 for FY2021, which is 33.61% up from last year.
  • Per Foghorn Therapeutics' latest filing, its Amortization of Deferred Charges stood at $58,000 for Q4 2021, which was down 34.09% from $88,000 recorded in Q3 2021.
  • In the past 5 years, Foghorn Therapeutics' Amortization of Deferred Charges ranged from a high of $88,000 in Q3 2021 and a low of $53,000 during Q3 2020.
  • Over the past 2 years, Foghorn Therapeutics' median Amortization of Deferred Charges value was $63,000 (recorded in 2020), while the average stood at $69,500.
  • The largest annual percentage gain for Foghorn Therapeutics' Amortization of Deferred Charges in the last 5 years was 66.04% (2021), contrasted with its biggest fall of 1.69% (2021).
  • Foghorn Therapeutics' Amortization of Deferred Charges (Quarterly) stood at $59,000 in 2020, then declined by 1.69% to $58,000 in 2021.
  • Its Amortization of Deferred Charges was $58,000 in Q4 2021, compared to $88,000 in Q3 2021 and $87,000 in Q2 2021.